COVID-19 and Pulmonary fibrosis
We would like to introduce an update regarding the relationship between pulmonary fibrosis and COVID-19, which is currently spreading worldwide.
SARS-CoV-2 infection and subsequent continued inflammation have induced the features shown in below in COVID-19 patients. (Rothan et al., J Autoimmun., 2020; Weiren et al., Preprint, 2020 ).
Similar features have been reported in patients with Idiopathic pulmonary fibrosis (IPF) and a mouse model of Bleomycin (BLM)-induced IPF (Li et al., Am J Physiol Lung Cell Mol Physiol., 2008; Le et al., J Immunol., 2014 ).
At SMC, we have a broad experience with our BLM-IPF model for pulmonary fibrosis, and can utilize our expertise in analysis to assess the above features through qPCR, ELISA and histopathology.
It has been reported that that IPF can be triggered by viral-induced lung damage, so there is a growing need for the development of fibrosis therapeutics.
If you are researching the prevention and treatment of fibrosis, please consider our IPF model.
We have a variety of fibrotic and inflammatory disease models as well as the IPF model, through which we provide pharmacological efficacy testing services.